StockData
AstraZeneca PLC logo

AstraZeneca PLC (AZN) KPIs and segments

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của AstraZeneca · năm tài chính kết thúc December 31 (calendar fiscal year; FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

Nhìn nhanh KPI của AstraZeneca: 49 chỉ số vận hành, trong đó có Total revenue, Oncology — Worldwide product sales và Cardiovascular, Renal & Metabolism (CVRM), lấy từ 142 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
The Americas($M)
42,20138,54434,754
Rest of Europe($M)
41,59637,88440,638
United Kingdom($M)
21,98320,13919,616
Asia, Africa And Australasia($M)
8,2947,4686,111
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1
Total revenue ($M)($M)7
15,38415,28815,50315,19114,45713,58814,89113,56512,93812,67912,02411,492
Product sales ($M)($M)
14,51014,38614,53814,36513,79512,87513,36212,94712,45212,17711,32311,018
Alliance revenue ($M)($M)6
874825959815654639714559482457424377
Enhertu (Daiichi Sankyo alliance) revenue ($M)($M)
550508507457436392361344339281266
Tezspire (Amgen alliance) revenue ($M)($M)
218154220168155133123104778074
Beyfortus (Sanofi / Sobi alliance) revenue ($M)($M)
32116170142271614972041
Datroway (Daiichi Sankyo alliance) revenue ($M)($M)
5142392410
Other royalty income ($M)($M)
222922242118
Other alliance revenue ($M)($M)
11124264262721119
Collaboration revenue ($M)($M)
0776118748155944527797
United States (US) — Total revenue ($M)($M)3
6,6866,2056,9326,5486,3235,6466,5326,0085,5715,1245,1014,859
United States (US) — Share of total revenue (%)(%)
43.0%41.0%45.0%43.0%44.0%42.0%44.0%44.0%43.0%40.0%42.0%42.0%
United States (US) — Revenue YoY actual (%)(%)
6.0%10.0%6.0%9.0%13.0%10.0%28.0%23.0%17.0%19.0%7.0%5.0%
United States (US) — Revenue YoY at constant exchange rates / CER (%)(%)
6.0%10.0%6.0%9.0%14.0%10.0%28.0%23.0%17.0%19.0%6.0%4.0%
Emerging Markets — Total revenue ($M)($M)5
3,9214,3983,6463,9603,7543,9433,1343,4233,3863,7322,7832,964
Emerging Markets — Share of total revenue (%)(%)
25.0%29.0%24.0%26.0%26.0%29.0%21.0%25.0%26.0%29.0%23.0%26.0%
Emerging Markets — Revenue YoY actual (%)(%)
4.0%12.0%16.0%16.0%11.0%6.0%13.0%15.0%9.0%18.0%2.0%4.0%
Emerging Markets — Revenue YoY at constant exchange rates / CER (%)(%)
0.0%6.0%14.0%15.0%13.0%12.0%19.0%23.0%18.0%26.0%8.0%12.0%
China — Total revenue ($M)($M)3
1,5871,9231,3751,7641,7101,8051,3641,6711,6301,7481,3821,452
China — Share of total revenue (%)(%)
10.0%13.0%9.0%12.0%12.0%13.0%9.0%12.0%13.0%14.0%11.0%13.0%
China — Revenue YoY actual (%)(%)
-7.0%7.0%1.0%6.0%5.0%3.0%-1.0%15.0%13.0%9.0%16.0%-6.0%
China — Revenue YoY at constant exchange rates / CER (%)(%)
-13.0%2.0%1.0%5.0%5.0%5.0%-3.0%15.0%18.0%13.0%16.0%1.0%
Emerging Markets excluding China — Total revenue ($M)($M)3
2,3342,4752,2712,1962,0432,1381,7701,7521,7561,9841,4011,513
Emerging Markets excluding China — Share of total revenue (%)(%)
15.0%16.0%15.0%14.0%14.0%16.0%12.0%13.0%14.0%16.0%12.0%13.0%
Emerging Markets excluding China — Revenue YoY actual (%)(%)
14.0%16.0%28.0%25.0%16.0%8.0%26.0%16.0%5.0%27.0%-9.0%15.0%
Emerging Markets excluding China — Revenue YoY at constant exchange rates / CER (%)(%)
11.0%9.0%24.0%25.0%21.0%17.0%42.0%31.0%18.0%40.0%2.0%25.0%
Europe — Total revenue ($M)($M)3
3,4173,4053,5793,3343,0662,7593,9482,8752,7322,6342,8802,392
Europe — Share of total revenue (%)(%)
22.0%22.0%23.0%22.0%21.0%20.0%27.0%21.0%21.0%21.0%24.0%21.0%
Europe — Revenue YoY actual (%)(%)
11.0%23.0%-9.0%16.0%12.0%5.0%37.0%22.0%24.0%22.0%25.0%16.0%
Europe — Revenue YoY at constant exchange rates / CER (%)(%)
7.0%9.0%-15.0%10.0%8.0%9.0%35.0%22.0%24.0%19.0%17.0%9.0%
Established Rest of World (Japan, Canada, Australia & New Zealand) — Total revenue ($M)($M)3
1,3611,2801,3451,3491,3151,2391,2771,2601,2491,1891,2591,276
Established Rest of World (Japan, Canada, Australia & New Zealand) — Share of total revenue (%)(%)
9.0%8.0%9.0%9.0%9.0%9.0%9.0%9.0%10.0%9.0%10.0%11.0%
Established Rest of World (Japan, Canada, Australia & New Zealand) — Revenue YoY actual (%)(%)
4.0%3.0%5.0%7.0%5.0%4.0%1.0%-1.0%-5.0%-5.0%-9.0%-10.0%
Established Rest of World (Japan, Canada, Australia & New Zealand) — Revenue YoY at constant exchange rates / CER (%)(%)
8.0%2.0%7.0%5.0%2.0%9.0%2.0%4.0%6.0%2.0%-6.0%-6.0%
Oncology — Worldwide product sales ($M)($M)16
6,7136,2366,4706,1435,8545,2315,3415,1974,9764,7604,4534,389
Oncology — Worldwide YoY actual (%)(%)
15.0%19.0%21.0%18.0%18.0%10.0%20.0%18.0%14.0%21.0%19.0%16.0%
Oncology — Worldwide YoY CER (%)(%)
13.0%15.0%19.0%17.0%17.0%13.0%22.0%21.0%18.0%24.0%19.0%17.0%
Oncology — US product sales ($M)($M)1
3,1632,7883,1282,8932,7702,3972,6402,4842,3022,0842,0671,986
Oncology — US YoY (%)(%)
14.0%16.0%18.0%16.0%20.0%15.0%28.0%25.0%17.0%22.0%16.0%16.0%
Oncology — Emerging Markets product sales ($M)($M)2
1,5221,5211,3421,3801,3101,3181,0571,1451,0981,202904971
Oncology — Emerging Markets YoY actual (%)(%)
16.0%15.0%27.0%21.0%19.0%10.0%17.0%18.0%11.0%24.0%11.0%4.0%
Oncology — Emerging Markets YoY CER (%)(%)
12.0%10.0%25.0%21.0%22.0%16.0%27.0%28.0%22.0%33.0%18.0%13.0%
Oncology — Europe product sales ($M)($M)2
1,4081,3781,3811,2841,1831,0321,0821,0321,015953903849
Oncology — Europe YoY actual (%)(%)
19.0%34.0%28.0%24.0%17.0%8.0%20.0%22.0%24.0%26.0%31.0%22.0%
Oncology — Europe YoY CER (%)(%)
14.0%18.0%19.0%17.0%12.0%12.0%18.0%22.0%24.0%23.0%22.0%15.0%
Oncology — Established RoW product sales ($M)($M)2
620549619586591484562536561521579583
Oncology — Established RoW YoY actual (%)(%)
5.0%13.0%10.0%9.0%5.0%-7.0%-3.0%-8.0%-9.0%6.0%28.0%28.0%
Oncology — Established RoW YoY CER (%)(%)
10.0%12.0%12.0%7.0%2.0%-2.0%-3.0%-3.0%2.0%16.0%32.0%35.0%
Tagrisso (osimertinib) — Worldwide product sales ($M)($M)6
1,9411,8331,9021,8641,8101,6791,7031,6741,6081,5951,4191,465
Imfinzi (durvalumab) — Worldwide product sales ($M)($M)6
1,8541,6941,7471,6011,4551,2611,2541,2031,1471,1131,1351,126
Calquence (acalabrutinib) — Worldwide product sales ($M)($M)6
1,022923967916872762808813790718675654
Lynparza (olaparib) — Worldwide product sales ($M)($M)6
829781878837838726844778744705741702
Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M)($M)6
3383242922572301981481481271228373
Truqap (capivasertib) — Worldwide product sales ($M)($M)6
23319823319317013216312592506
Zoladex (goserelin) — Worldwide product sales ($M)($M)6
304304254285284283242268273276254239
Imjudo (tremelimumab) — Worldwide product sales ($M)($M)6
83779384898073727462
Datroway (datopotamab deruxtecan — direct product sales) — Worldwide product sales ($M)($M)4
411
Other Oncology medicines — Worldwide product sales ($M)($M)6
102101103106106110971061091075054
Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M)($M)14
2,7713,2403,0443,2143,2613,2453,1323,1523,1533,0122,6982,683
Cardiovascular, Renal & Metabolism (CVRM) — Worldwide YoY actual (%)(%)
-15.0%0.0%-3.0%2.0%3.0%8.0%16.0%17.0%18.0%19.0%18.0%14.0%
Cardiovascular, Renal & Metabolism (CVRM) — Worldwide YoY CER (%)(%)
-18.0%-6.0%-6.0%0.0%3.0%12.0%17.0%20.0%22.0%22.0%18.0%16.0%
Cardiovascular, Renal & Metabolism (CVRM) — US product sales ($M)($M)1
375593709662665687853739735748780690
Cardiovascular, Renal & Metabolism (CVRM) — US YoY (%)(%)
-44.0%-14.0%-17.0%-10.0%-10.0%-8.0%9.0%7.0%11.0%20.0%12.0%9.0%
Cardiovascular, Renal & Metabolism (CVRM) — Emerging Markets product sales ($M)($M)2
1,3461,6531,2701,5591,5121,5521,1931,3961,3841,3651,0781,161
Cardiovascular, Renal & Metabolism (CVRM) — Emerging Markets YoY actual (%)(%)
-11.0%7.0%6.0%12.0%9.0%14.0%11.0%20.0%17.0%17.0%15.0%7.0%
Cardiovascular, Renal & Metabolism (CVRM) — Emerging Markets YoY CER (%)(%)
-15.0%0.0%4.0%11.0%11.0%20.0%14.0%25.0%24.0%24.0%19.0%15.0%
Cardiovascular, Renal & Metabolism (CVRM) — Europe product sales ($M)($M)2
887868895806889807886826843716679657
Cardiovascular, Renal & Metabolism (CVRM) — Europe YoY actual (%)(%)
0.0%8.0%1.0%-2.0%5.0%13.0%31.0%26.0%38.0%29.0%38.0%40.0%
Cardiovascular, Renal & Metabolism (CVRM) — Europe YoY CER (%)(%)
-4.0%-5.0%-6.0%-8.0%1.0%17.0%28.0%26.0%38.0%26.0%28.0%32.0%
Cardiovascular, Renal & Metabolism (CVRM) — Established RoW product sales ($M)($M)2
163126170187195199200191191183161175
Cardiovascular, Renal & Metabolism (CVRM) — Established RoW YoY actual (%)(%)
-16.0%-37.0%-15.0%-2.0%2.0%9.0%24.0%9.0%-14.0%-2.0%5.0%6.0%
Cardiovascular, Renal & Metabolism (CVRM) — Established RoW YoY CER (%)(%)
-12.0%-38.0%-13.0%-4.0%-2.0%13.0%24.0%14.0%-3.0%7.0%8.0%10.0%
Farxiga / Forxiga (dapagliflozin) — Worldwide product sales ($M)($M)6
1,8042,1932,0592,1342,1502,0571,9331,9381,9401,8451,6061,554
Lokelma (sodium zirconium cyclosilicate) — Worldwide product sales ($M)($M)6
221199181189175153150143136114112102
Brilinta / Brilique (ticagrelor) — Worldwide product sales ($M)($M)6
80105158146215305341327342323329331
Crestor (rosuvastatin) — Worldwide product sales ($M)($M)6
331354275305319316261304292297247275
Seloken / Toprol-XL (metoprolol) — Worldwide product sales ($M)($M)6
157180139160148161140150150165144153
Roxadustat (evrenzo) — Worldwide product sales ($M)($M)6
144347777278749388756374
Wainua (eplontersen) — Worldwide product sales ($M)($M)6
7051695944394223165
Other CVRM medicines — Worldwide product sales ($M)($M)6
911151161441381361321201301415866
Respiratory & Immunology (R&I) — Worldwide product sales ($M)($M)14
2,2072,1502,1472,0851,9881,9471,9851,8301,7971,8041,5901,451
Respiratory & Immunology (R&I) — Worldwide YoY actual (%)(%)
11.0%10.0%8.0%14.0%11.0%8.0%25.0%26.0%21.0%14.0%10.0%2.0%
Respiratory & Immunology (R&I) — Worldwide YoY CER (%)(%)
9.0%6.0%6.0%12.0%10.0%11.0%26.0%28.0%24.0%16.0%10.0%3.0%
Respiratory & Immunology (R&I) — US product sales ($M)($M)1
9828809841,013977865996852830737647609
Respiratory & Immunology (R&I) — US YoY (%)(%)
0.0%2.0%-1.0%19.0%18.0%17.0%54.0%40.0%23.0%19.0%-6.0%-8.0%
Respiratory & Immunology (R&I) — Emerging Markets product sales ($M)($M)2
490565468445381529408457444588456422
Respiratory & Immunology (R&I) — Emerging Markets YoY actual (%)(%)
29.0%7.0%15.0%-3.0%-14.0%-10.0%-11.0%8.0%23.0%10.0%34.0%14.0%
Respiratory & Immunology (R&I) — Emerging Markets YoY CER (%)(%)
24.0%2.0%12.0%-3.0%-13.0%-6.0%-7.0%14.0%34.0%16.0%41.0%23.0%
Respiratory & Immunology (R&I) — Europe product sales ($M)($M)2
509498477425422378391346350330317266
Respiratory & Immunology (R&I) — Europe YoY actual (%)(%)
21.0%32.0%22.0%23.0%21.0%14.0%23.0%30.0%21.0%13.0%22.0%9.0%
Respiratory & Immunology (R&I) — Europe YoY CER (%)(%)
16.0%17.0%14.0%16.0%16.0%19.0%21.0%30.0%21.0%11.0%14.0%2.0%
Respiratory & Immunology (R&I) — Established RoW product sales ($M)($M)2
226207218202208175190175173149170154
Respiratory & Immunology (R&I) — Established RoW YoY actual (%)(%)
9.0%19.0%15.0%16.0%20.0%17.0%12.0%13.0%8.0%6.0%10.0%3.0%
Respiratory & Immunology (R&I) — Established RoW YoY CER (%)(%)
11.0%15.0%17.0%15.0%19.0%24.0%12.0%18.0%14.0%11.0%12.0%7.0%
Fasenra (benralizumab) — Worldwide product sales ($M)($M)6
570483530530502418471436423358420389
Breztri Aerosphere (budesonide/glycopyrronium/formoterol) — Worldwide product sales ($M)($M)6
346353294323283300257266235219199171
Symbicort (budesonide/formoterol) — Worldwide product sales ($M)($M)6
671747704742715723684705722769520555
Tezspire (tezepelumab — direct product sales) — Worldwide product sales ($M)($M)6
17214914111911287806857433521
Saphnelo (anifrolumab) — Worldwide product sales ($M)($M)6
209171203180167136147124112918976
Airsupra (albuterol/budesonide) — Worldwide product sales ($M)($M)4
5037514542282521147
Pulmicort (budesonide) — Worldwide product sales ($M)($M)6
12014916193106158164138155224219148
Other Respiratory & Immunology medicines — Worldwide product sales ($M)($M)6
6961635361971577279938067
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M)($M)9
9990272274157143378355112212345224
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide YoY actual (%)(%)
-37.0%-37.0%-28.0%-23.0%40.0%-32.0%10.0%59.0%28.0%-40.0%-69.0%-74.0%
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide YoY CER (%)(%)
-38.0%-41.0%-30.0%-24.0%42.0%-30.0%8.0%61.0%42.0%-40.0%-70.0%-74.0%
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — US product sales ($M)($M)1
3523545473278014528275915
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — US YoY (%)(%)
-52.0%-15.0%-32.0%-63.0%2.0%35.0%-74.0%-95.0%
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets product sales ($M)($M)2
314059403883453741903132
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets YoY actual (%)(%)
-18.0%-52.0%32.0%7.0%-6.0%-8.0%46.0%18.0%-10.0%-13.0%-90.0%-76.0%
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets YoY CER (%)(%)
-24.0%-55.0%26.0%7.0%-1.0%-3.0%58.0%37.0%4.0%-12.0%-90.0%-75.0%
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Europe product sales ($M)($M)2
9161531522426219108774195122
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Europe YoY actual (%)(%)
-62.0%-40.0%-30.0%41.0%-65.0%12.0%23.0%-55.0%-27.0%-42.0%-33.0%
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Europe YoY CER (%)(%)
-64.0%-47.0%-33.0%37.0%-64.0%9.0%20.0%-53.0%-26.0%-45.0%-35.0%
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW product sales ($M)($M)2
2411628227346536216055
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY actual (%)(%)
7.0%67.0%-82.0%-57.0%-39.0%-67.0%-43.0%18.0%36.0%-87.0%-76.0%-78.0%
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY CER (%)(%)
6.0%55.0%-82.0%-57.0%-40.0%-67.0%-44.0%23.0%55.0%-86.0%-75.0%-77.0%
Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M)($M)6
47245994983013013428265450
FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M)($M)6
1881401221001491002713875
Other Vaccines & Immune Therapies — Worldwide product sales ($M)($M)6
34581001-2006
Rare Disease (Alexion) — Worldwide product sales ($M)($M)11
2,4902,4202,3742,4162,2942,0422,2772,1482,1472,0961,9711,974
Rare Disease (Alexion) — Worldwide YoY actual (%)(%)
9.0%19.0%4.0%12.0%7.0%-3.0%16.0%9.0%10.0%12.0%9.0%13.0%
Rare Disease (Alexion) — Worldwide YoY CER (%)(%)
8.0%15.0%3.0%11.0%7.0%0.0%17.0%11.0%14.0%16.0%9.0%14.0%
Rare Disease (Alexion) — US product sales ($M)($M)1
1,4521,3721,4241,4151,3461,2371,4211,3251,3111,2071,2321,179
Rare Disease (Alexion) — US YoY (%)(%)
8.0%11.0%0.0%7.0%3.0%3.0%15.0%12.0%10.0%10.0%7.0%9.0%
Rare Disease (Alexion) — Emerging Markets product sales ($M)($M)2
305347248307278205221174203251136163
Rare Disease (Alexion) — Emerging Markets YoY actual (%)(%)
10.0%69.0%12.0%76.0%37.0%-18.0%63.0%7.0%35.0%45.0%18.0%49.0%
Rare Disease (Alexion) — Emerging Markets YoY CER (%)(%)
6.0%57.0%10.0%73.0%48.0%-10.0%84.0%29.0%67.0%73.0%46.0%70.0%
Rare Disease (Alexion) — Europe product sales ($M)($M)2
442431422410412360379395392401364397
Rare Disease (Alexion) — Europe YoY actual (%)(%)
7.0%20.0%11.0%4.0%5.0%-10.0%4.0%0.0%3.0%4.0%4.0%15.0%
Rare Disease (Alexion) — Europe YoY CER (%)(%)
3.0%6.0%4.0%-2.0%1.0%-7.0%2.0%0.0%3.0%1.0%-3.0%8.0%
Rare Disease (Alexion) — Established RoW product sales ($M)($M)2
291270280284258240256254241237239235
Rare Disease (Alexion) — Established RoW YoY actual (%)(%)
13.0%13.0%9.0%12.0%7.0%1.0%7.0%8.0%7.0%12.0%18.0%16.0%
Rare Disease (Alexion) — Established RoW YoY CER (%)(%)
20.0%13.0%11.0%9.0%2.0%6.0%8.0%14.0%18.0%21.0%22.0%22.0%
Ultomiris (ravulizumab) — Worldwide product sales ($M)($M)6
1,3141,2701,2651,2251,1771,0501,0891,031946859825777
Soliris (eculizumab) — Worldwide product sales ($M)($M)6
389389401462530444543606700739715781
Strensiq (asfotase alfa) — Worldwide product sales ($M)($M)6
536517490441395352420343340313305285
Koselugo (selumetinib) — Worldwide product sales ($M)($M)6
1771701632241371381651191141328587
Other Rare Disease medicines — Worldwide product sales ($M)($M)6
747455645558
Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M)($M)6
230250231233241267249265267293266297
Other Medicines (Established / Legacy Brands) — Worldwide YoY actual (%)(%)
-4.0%-7.0%-7.0%-12.0%-10.0%-9.0%-6.0%-11.0%-11.0%-6.0%-30.0%-27.0%
Other Medicines (Established / Legacy Brands) — Worldwide YoY CER (%)(%)
-6.0%-9.0%-7.0%-12.0%-9.0%-5.0%-4.0%-7.0%-5.0%1.0%-28.0%-22.0%
Other Medicines (Established / Legacy Brands) — US product sales ($M)($M)1
19231492119243528242936
Other Medicines (Established / Legacy Brands) — US YoY (%)(%)
-9.0%22.0%-41.0%-73.0%-26.0%-20.0%-18.0%-3.0%-13.0%-33.0%-9.0%-3.0%
Other Medicines (Established / Legacy Brands) — Emerging Markets product sales ($M)($M)2
166192168172186206171179179206151190
Other Medicines (Established / Legacy Brands) — Emerging Markets YoY actual (%)(%)
-10.0%-7.0%-2.0%-4.0%4.0%0.0%14.0%-6.0%-3.0%0.0%-16.0%-11.0%
Other Medicines (Established / Legacy Brands) — Emerging Markets YoY CER (%)(%)
-13.0%-9.0%-1.0%-3.0%5.0%4.0%17.0%0.0%5.0%11.0%-13.0%-4.0%
Other Medicines (Established / Legacy Brands) — Europe product sales ($M)($M)2
251525231619282224293819
Other Medicines (Established / Legacy Brands) — Europe YoY actual (%)(%)
52.0%-23.0%-10.0%4.0%-32.0%-35.0%-27.0%18.0%-7.0%31.0%36.0%-32.0%
Other Medicines (Established / Legacy Brands) — Europe YoY CER (%)(%)
51.0%-30.0%-14.0%3.0%-38.0%-30.0%-28.0%16.0%-7.0%30.0%34.0%-34.0%
Other Medicines (Established / Legacy Brands) — Established RoW product sales ($M)($M)2
202024291823262936344852
Other Medicines (Established / Legacy Brands) — Established RoW YoY actual (%)(%)
12.0%-15.0%-8.0%0.0%-50.0%-32.0%-46.0%-45.0%-38.0%-31.0%-66.0%-59.0%
Other Medicines (Established / Legacy Brands) — Established RoW YoY CER (%)(%)
14.0%-17.0%-6.0%-4.0%-50.0%-29.0%-45.0%-41.0%-32.0%-25.0%-65.0%-56.0%
Total projects in clinical development pipeline (count)3
183186197198196194191199189182178
Phase II & Phase III NME or major LCM projects in pipeline (count)
116118125122132132130139131123123
New Molecular Entities (NMEs) in late-stage pipeline (count)
2121202019181921201917
Regulatory approvals in major markets — US, EU, China, Japan (count)
15147128166979
Core gross profit ($M)($M)5
12,86312,62412,33412,41711,91411,36512,08911,11210,78010,4919,7389,444
Core gross margin (% of product sales)(%)
84.0%83.0%80.0%82.0%82.0%84.0%
Core gross profit YoY actual (%)(%)
8.0%11.0%2.0%12.0%11.0%8.0%24.0%18.0%13.0%15.0%11.0%6.0%
Core gross profit YoY CER (%)(%)
6.0%9.0%0.0%10.0%11.0%10.0%26.0%21.0%17.0%18.0%11.0%7.0%
Reported (IFRS) gross profit ($M)($M)
12,86112,61012,38512,39011,98411,34712,16610,48410,75510,4619,7169,397
Reported (IFRS) gross margin (%)(%)
84.0%82.0%80.0%82.0%83.0%84.0%
Core R&D expense ($M)($M)5
-3,662-3,461-3,731-3,550-3,453-3,088-3,573-3,068-2,872-2,698-2,914-2,485
Core R&D expense (% of total revenue)(%)
24.0%23.0%24.0%23.0%24.0%23.0%
Core R&D expense YoY actual (%)(%)
6.0%12.0%4.0%16.0%20.0%14.0%23.0%23.0%12.0%17.0%15.0%5.0%
Core R&D expense YoY CER (%)(%)
5.0%8.0%3.0%14.0%18.0%16.0%22.0%24.0%13.0%18.0%14.0%5.0%
Reported (IFRS) R&D expense ($M)($M)
-4,053-3,492-3,862-3,663-3,548-3,159-4,677-3,115-3,008-2,783-3,073-2,584
Reported (IFRS) R&D expense (% of total revenue)(%)
26.0%23.0%25.0%24.0%25.0%23.0%
Core SG&A expense ($M)($M)7
-4,050-3,859-4,453-3,822-3,802-3,457-4,275-3,605-3,735-3,413-4,034-3,355
Core SG&A expense (% of total revenue)(%)
26.0%25.0%29.0%25.0%26.0%25.0%
Core SG&A expense YoY actual (%)(%)
7.0%12.0%4.0%6.0%2.0%1.0%6.0%8.0%13.0%12.0%13.0%6.0%
Core SG&A expense YoY CER (%)(%)
4.0%7.0%2.0%4.0%1.0%4.0%7.0%9.0%16.0%13.0%12.0%7.0%
Reported (IFRS) SG&A expense ($M)($M)
-5,651-4,920-5,492-5,085-4,864-4,492-5,410-5,143-4,929-4,495-5,371-4,800
Reported (IFRS) SG&A expense (% of total revenue)(%)
37.0%32.0%35.0%33.0%34.0%33.0%
Core distribution expense ($M)($M)
-145-141-153-148-146-132-143-145-132-135-145-129
Core other operating income & expense ($M)($M)
152189101967111510124606510770
Core operating profit ($M)($M)7
5,1585,3524,0984,9934,5844,8034,1994,3184,1014,3102,7523,545
Core operating margin (% of total revenue)(%)
34.0%35.0%26.0%33.0%32.0%35.0%28.0%32.0%32.0%34.0%22.9%30.8%
Core operating profit YoY actual (%)(%)
12.0%11.0%-2.0%16.0%12.0%11.0%53.0%22.0%-4.0%9.0%5.0%4.0%
Core operating profit YoY CER (%)(%)
10.0%12.0%-5.0%13.0%14.0%12.0%58.0%27.0%1.0%15.0%6.0%9.0%
Reported (IFRS) operating profit ($M)($M)
3,1644,2462,9783,5833,5083,6742,0362,1062,7463,1151,2341,954
Reported (IFRS) operating margin (%)(%)
21.0%28.0%19.0%24.0%24.0%27.0%14.0%16.0%21.0%25.0%10.3%17.0%
Core adjustment — Total restructuring charges ($M)($M)
-100-60-57-7921-122-100-705-154-195-115-124
Core adjustment — Intangible asset amortisation & impairments ($M)($M)
-1,546-990-1,124-1,181-1,047-975-2,003-1,469-987-955-1,007-1,014
Core EPS ($ per share)($)5
2.632.582.122.382.172.492.092.081.982.061.451.73
Core EPS YoY actual (%)(%)
21.0%4.0%1.0%14.0%10.0%21.0%44.0%20.0%-8.0%7.0%5.0%4.0%
Core EPS YoY CER (%)(%)
18.0%5.0%-2.0%12.0%12.0%21.0%49.0%27.0%-3.0%13.0%7.0%9.0%
Reported (IFRS) basic EPS ($ per share)($)
1.611.991.501.641.581.880.970.921.241.410.620.89
Core net finance expense ($M)($M)
-340-281-269-305-303-215-310-329-285-245-259-223
Core income tax expense ($M)($M)
-731-1,058-543-1,002-911-714-640-753-741-867-242-624
EBITDA ($M)($M)1
5,0925,6124,4895,1324,8974,9584,3733,9234,0254,3702,5613,236
Depreciation, amortisation & impairment added back in EBITDA ($M)($M)
1,9281,3661,5111,5491,3891,2842,3371,8171,2791,2551,3271,282
FX sensitivity (+5% vs USD): EUR impact on annual Total Revenue ($M)($M)14
499499499-461-461-461-461397397397397323
Net intangible assets carrying value ($M)($M)
37,72337,84637,92537,17739,42638,089
Total inventories carrying value ($M)($M)
6,9326,5576,4675,2885,6675,424
Property, plant and equipment (PP&E) — net carrying value ($M)($M)
13,61512,96211,63710,2529,6309,402
Right-of-use (ROU) lease assets — net carrying value ($M)($M)
2,6851,7411,5921,3951,2031,100
Net debt ($M)($M)3
26,91225,94423,37423,96525,22726,06724,57026,34826,32426,44922,51023,371
Total cash, cash equivalents & current investments ($M)($M)2
4,9687,6755,7418,1827,1085,3955,6544,9307,0768,0215,9625,115
Cash and cash equivalents ($M)($M)
4,8937,5605,7118,1437,0585,2305,4884,7976,9167,8415,8404,871
Other current fixed-income investments ($M)($M)
75115303950165166133160180122244
Total gross debt (loans, bonds, overdrafts & lease liabilities) ($M)($M)4
-32,239-33,918-29,622-32,632-32,839-31,646-30,295-31,562-33,533-34,551-28,622-28,576
Non-current loans & bonds ($M)($M)
-23,683-24,454-24,715-24,700-24,714-26,692-26,506-28,887-27,225-27,259-22,365-22,225
Current portion of loans & bonds ($M)($M)
-2,859-4,567-2,460-4,461-4,461-2,010-2,007-12-2,018-4,593-4,614-4,857
Lease liabilities ($M)($M)
-2,748-1,888-1,803-1,758-1,633-1,551-1,452-1,422-1,241-1,242-1,128-979
Short-term borrowings & bank overdrafts ($M)($M)
-542-597-644-622-561-445-330-769-596-477-515-515
Net financial derivatives fair value in Net Debt ($M)($M)
359299507485504184712841338115090
Net cash inflow from operating activities ($M)($M)7
2,8653,3592,3425,1343,3863,7132,9073,3833,0852,4862,3803,114
Net cash inflow before financing activities ($M)($M)
-471,5678963,1331,2782,4601,7261,869213731,3031,893
Movement in working capital & short-term provisions ($M)($M)
-438-1,000-1,201835-345-426-35041-129-455
Income tax paid ($M)($M)
-1,525-526-652-644-1,186-363-772-641-907-430-656-649
Interest paid ($M)($M)
-189-441-247-446-201-422-238-492-242-341-255-343
Purchase of property, plant and equipment (Capex) ($M)($M)
-763-547-1,036-686-659-429-708-417-382-417-525-319
Purchase of intangible assets ($M)($M)
-2,342-991-251-1,040-1,264-540-247-941-286-1,188-421-560
Dividends paid to shareholders ($M)($M)
-1-3,287-3-1,611-10-3,347-3-1,576-17-3,033-2-1,410
U.S. Retail Sales — Pharmacies and Drug Stores, Seasonally Adjusted ($M)1
U.S. Personal Consumption Expenditures — Health Care Services, SAAR ($B)($M)
3,7903,7003,6673,6153,5303,4653,4183,3583,2883,2443,1593,079
Consolidated Total Revenue ($M)($M)19
15,38415,28815,50315,19114,45713,58814,89113,56512,93812,67912,02411,492
Total assets ($M)($M)8
115,833114,074112,422104,035104,340101,119
Net cash inflow from operating activities ($M)($M)3
2,8653,3592,3425,1343,3863,7132,9073,3833,0852,4862,3803,114

303 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar & IFRS reporting: AstraZeneca PLC (CIK 0000901832) reports under IFRS in millions of U.S. dollars ($M) with a fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026; monthly Total Voting Rights through September 30, 2026).
  • Core operational & commercial KPIs (Groups 1–4) cover: (1) Revenue by stream (Product Sales $55,702M, Alliance Revenue $3,053M led by Enhertu $1,945M, Tezspire $630M, Beyfortus $284M & Datroway $49M, and Collaboration Revenue $701M in FY2025) and Regional Total Revenue across the US ($25,571M), Emerging Markets ($14,487M split into China $6,654M and Ex-China Emerging Markets $7,833M), Europe ($12,727M), and Established RoW ($5,954M) with published Actual YoY % and Constant Exchange Rate (CER) YoY % growth; (2) Product Sales across all 5 Therapy Areas (Oncology, CVRM, R&I, V&I/ID, Rare Disease) and 34 continuous medicines broken down by all 5 geographic regions (World, US, Emerging Markets, Europe, Established RoW); (3) U.S. Gross-to-Net (GTN) Sales Rebates, Chargebacks & Returns reconciliation (FY2025 Gross U.S. Product Sales of $47,385M less $23,941M total GTN deductions — including $13,963M Managed Care & Medicare, $5,113M Chargebacks, $2,527M Medicaid, $483M Cash Discounts, $149M Customer Returns, $99M Branded Prescription Drug Fee, and $1,607M Other — yielding $23,444M Net U.S. Product Sales), Global/US/China/Rare Disease rebate reserves, U.S. GTN sensitivity %, and Top 3 U.S. Wholesaler concentration (78% of U.S. trade receivables; #1 wholesaler $8,218M and #2 wholesaler $5,957M in FY2025); and (4) R&D Clinical Pipeline (183 total projects, 116 Phase II/III projects, 21 late-stage NMEs, and 15 regulatory approvals in Q2 2026), Clinical Trial Transparency, Research Animals, and U.S. FDA Inspections / Form 483 Observations / Recalls.
  • Extended operational & financial KPIs (Groups 5–12) cover Core vs. Reported P&L & FX sensitivities (+5% impact of EUR, CNY, JPY, GBP, SEK on Total Revenue & Core Operating Profit), Individual Medicine Intangible Assets (C5 Soliris/Ultomiris $9,990M, Strensiq/Kanuma $5,375M, Alexion IPR&D $3,350M, Calquence $2,110M, Enhertu $2,188M, Baxdrostat $1,813M, Datroway $1,561M), Inventories by stage, PP&E by country, Provisions rollforward, Partner Payables to Daiichi Sankyo & Bond Avillion, Monthly Total Voting Rights (1,551,053,289 shares at Sep 2026), Net Debt ($26,912M at Q2 2026), Subsidiary & Statutory Entity self-disclosures (AstraZeneca UK Limited, MedImmune UK Limited, and the $9.63B AstraZeneca US 401(k) Plan from Form 11-K), Global Workforce (96,800 employees at FY2025), Share Plans (PSP/GRSP/RSP), Defined Benefit Pensions (UK, Sweden, Other), Access to Healthcare reach (108M people), Scope 1/2/3 GHG emissions, FRED industry benchmarks, and Consolidated Financial Statements (with Q1/Q3/Q4 backfill).
  • Parent-only standalone financial statements in the UK Annual Report are prepared under FRS 101 (UK GAAP) on an annual-only basis for AstraZeneca PLC as a non-trading holding company ($0 product sales), so Consolidated − Standalone subtraction is not applicable. All values are strictly as published (with verbatim quotes on hover for text-extracted cells), plus period-splitting (Q2 = H1 − Q1; Q3 = 9M − H1; Q4 = FY − 9M) displayed in italic with the formula.

Không hiện vì thiếu các kỳ gần đây (325)

  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Emerging Markets product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Emerging Markets YoY actual (%)
  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Emerging Markets product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Emerging Markets YoY CER (%)
  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Established RoW product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Established RoW YoY actual (%)
  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Established RoW product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Established RoW YoY CER (%)
  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Emerging Markets product sales ($M) › Truqap (capivasertib) — Emerging Markets YoY actual (%)
  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Emerging Markets product sales ($M) › Truqap (capivasertib) — Emerging Markets YoY CER (%)
  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Europe product sales ($M) › Truqap (capivasertib) — Europe YoY actual (%)
  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Europe product sales ($M) › Truqap (capivasertib) — Europe YoY CER (%)
  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Established RoW product sales ($M) › Truqap (capivasertib) — Established RoW YoY actual (%)
  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Established RoW product sales ($M) › Truqap (capivasertib) — Established RoW YoY CER (%)
  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide YoY actual (%)
  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide YoY CER (%)
  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — US product sales ($M) › Faslodex (fulvestrant) — US YoY (%)
  • Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Emerging Markets product sales ($M) › Faslodex (fulvestrant) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Emerging Markets product sales ($M) › Faslodex (fulvestrant) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Europe product sales ($M) › Faslodex (fulvestrant) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Europe product sales ($M) › Faslodex (fulvestrant) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Established RoW product sales ($M) › Faslodex (fulvestrant) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Established RoW product sales ($M) › Faslodex (fulvestrant) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — US product sales ($M) › Orpathys (savolitinib) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Emerging Markets product sales ($M) › Orpathys (savolitinib) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Emerging Markets product sales ($M) › Orpathys (savolitinib) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Europe product sales ($M) › Orpathys (savolitinib) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Europe product sales ($M) › Orpathys (savolitinib) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Established RoW product sales ($M) › Orpathys (savolitinib) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Established RoW product sales ($M) › Orpathys (savolitinib) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — US product sales ($M) › Iressa (gefitinib) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Emerging Markets product sales ($M) › Iressa (gefitinib) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Emerging Markets product sales ($M) › Iressa (gefitinib) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Europe product sales ($M) › Iressa (gefitinib) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Europe product sales ($M) › Iressa (gefitinib) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Established RoW product sales ($M) › Iressa (gefitinib) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Established RoW product sales ($M) › Iressa (gefitinib) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — US product sales ($M) › Casodex (bicalutamide) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Emerging Markets product sales ($M) › Casodex (bicalutamide) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Emerging Markets product sales ($M) › Casodex (bicalutamide) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Europe product sales ($M) › Casodex (bicalutamide) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Europe product sales ($M) › Casodex (bicalutamide) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Established RoW product sales ($M) › Casodex (bicalutamide) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Established RoW product sales ($M) › Casodex (bicalutamide) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — US product sales ($M) › Arimidex (anastrozole) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Emerging Markets product sales ($M) › Arimidex (anastrozole) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Emerging Markets product sales ($M) › Arimidex (anastrozole) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Europe product sales ($M) › Arimidex (anastrozole) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Europe product sales ($M) › Arimidex (anastrozole) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Established RoW product sales ($M) › Arimidex (anastrozole) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Established RoW product sales ($M) › Arimidex (anastrozole) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — US product sales ($M) › Etcamah (launched Q2 2026) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Europe product sales ($M) › Etcamah (launched Q2 2026) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Europe product sales ($M) › Etcamah (launched Q2 2026) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Established RoW product sales ($M) › Etcamah (launched Q2 2026) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Established RoW product sales ($M) › Etcamah (launched Q2 2026) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Wainua (eplontersen) — Worldwide product sales ($M) › Wainua (eplontersen) — Emerging Markets product sales ($M) › Wainua (eplontersen) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Wainua (eplontersen) — Worldwide product sales ($M) › Wainua (eplontersen) — Emerging Markets product sales ($M) › Wainua (eplontersen) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Wainua (eplontersen) — Worldwide product sales ($M) › Wainua (eplontersen) — Europe product sales ($M) › Wainua (eplontersen) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Wainua (eplontersen) — Worldwide product sales ($M) › Wainua (eplontersen) — Europe product sales ($M) › Wainua (eplontersen) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — US product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — US product sales ($M) › Bydureon (exenatide ER) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Emerging Markets product sales ($M) › Bydureon (exenatide ER) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Emerging Markets product sales ($M) › Bydureon (exenatide ER) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Europe product sales ($M) › Bydureon (exenatide ER) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Europe product sales ($M) › Bydureon (exenatide ER) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Established RoW product sales ($M) › Bydureon (exenatide ER) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Established RoW product sales ($M) › Bydureon (exenatide ER) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — US product sales ($M) › Onglyza (saxagliptin) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Emerging Markets product sales ($M) › Onglyza (saxagliptin) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Emerging Markets product sales ($M) › Onglyza (saxagliptin) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Europe product sales ($M) › Onglyza (saxagliptin) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Europe product sales ($M) › Onglyza (saxagliptin) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Established RoW product sales ($M) › Onglyza (saxagliptin) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Established RoW product sales ($M) › Onglyza (saxagliptin) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — US product sales ($M) › Byetta (exenatide) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Emerging Markets product sales ($M) › Byetta (exenatide) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Emerging Markets product sales ($M) › Byetta (exenatide) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Europe product sales ($M) › Byetta (exenatide) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Europe product sales ($M) › Byetta (exenatide) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Established RoW product sales ($M) › Byetta (exenatide) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Established RoW product sales ($M) › Byetta (exenatide) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — US product sales ($M) › Atacand (candesartan) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Emerging Markets product sales ($M) › Atacand (candesartan) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Emerging Markets product sales ($M) › Atacand (candesartan) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Europe product sales ($M) › Atacand (candesartan) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Europe product sales ($M) › Atacand (candesartan) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Established RoW product sales ($M) › Atacand (candesartan) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Established RoW product sales ($M) › Atacand (candesartan) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — US product sales ($M) › Other Diabetes medicines — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Emerging Markets product sales ($M) › Other Diabetes medicines — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Emerging Markets product sales ($M) › Other Diabetes medicines — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Europe product sales ($M) › Other Diabetes medicines — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Europe product sales ($M) › Other Diabetes medicines — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Established RoW product sales ($M) › Other Diabetes medicines — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Established RoW product sales ($M) › Other Diabetes medicines — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Tezspire (tezepelumab — direct product sales) — Worldwide product sales ($M) › Tezspire (tezepelumab — direct product sales) — Emerging Markets product sales ($M) › Tezspire (tezepelumab — direct product sales) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Tezspire (tezepelumab — direct product sales) — Worldwide product sales ($M) › Tezspire (tezepelumab — direct product sales) — Emerging Markets product sales ($M) › Tezspire (tezepelumab — direct product sales) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Saphnelo (anifrolumab) — Worldwide product sales ($M) › Saphnelo (anifrolumab) — Emerging Markets product sales ($M) › Saphnelo (anifrolumab) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Saphnelo (anifrolumab) — Worldwide product sales ($M) › Saphnelo (anifrolumab) — Emerging Markets product sales ($M) › Saphnelo (anifrolumab) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Emerging Markets product sales ($M) › Airsupra (albuterol/budesonide) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Emerging Markets product sales ($M) › Airsupra (albuterol/budesonide) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — US product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Europe product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Established RoW product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — US product sales ($M) › Daliresp / Daxas (roflumilast) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Europe product sales ($M) › Daliresp / Daxas (roflumilast) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Europe product sales ($M) › Daliresp / Daxas (roflumilast) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Europe product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Europe product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Established RoW product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Established RoW product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Emerging Markets product sales ($M) › FluMist / Fluenz (influenza vaccine) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Emerging Markets product sales ($M) › FluMist / Fluenz (influenza vaccine) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Established RoW product sales ($M) › FluMist / Fluenz (influenza vaccine) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Established RoW product sales ($M) › FluMist / Fluenz (influenza vaccine) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — US product sales ($M) › Other Vaccines & Immune Therapies — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Europe product sales ($M) › Other Vaccines & Immune Therapies — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Europe product sales ($M) › Other Vaccines & Immune Therapies — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Synagis (palivizumab) — Worldwide product sales ($M) › Synagis (palivizumab) — US product sales ($M) › Synagis (palivizumab) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — US product sales ($M) › Evusheld (tixagevimab/cilgavimab) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — US product sales ($M) › Vaxzevria / COVID-19 Vaccine — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — US product sales ($M) › COVID-19 mAbs & vaccine combined — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Europe product sales ($M) › COVID-19 mAbs & vaccine combined — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Europe product sales ($M) › COVID-19 mAbs & vaccine combined — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Other Rare Disease medicines — Worldwide product sales ($M) › Other Rare Disease medicines — Emerging Markets product sales ($M) › Other Rare Disease medicines — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Other Rare Disease medicines — Worldwide product sales ($M) › Other Rare Disease medicines — Emerging Markets product sales ($M) › Other Rare Disease medicines — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Other Rare Disease medicines — Worldwide product sales ($M) › Other Rare Disease medicines — Established RoW product sales ($M) › Other Rare Disease medicines — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Other Rare Disease medicines — Worldwide product sales ($M) › Other Rare Disease medicines — Established RoW product sales ($M) › Other Rare Disease medicines — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — US product sales ($M) › Kanuma (sebelipase alfa) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Europe product sales ($M) › Kanuma (sebelipase alfa) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Europe product sales ($M) › Kanuma (sebelipase alfa) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Established RoW product sales ($M) › Kanuma (sebelipase alfa) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Established RoW product sales ($M) › Kanuma (sebelipase alfa) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Other Established / Legacy Medicines — Worldwide product sales ($M) › Other Established / Legacy Medicines — US product sales ($M) › Other Established / Legacy Medicines — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — US product sales ($M) › Losec / Prilosec (omeprazole) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Europe product sales ($M) › Losec / Prilosec (omeprazole) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Europe product sales ($M) › Losec / Prilosec (omeprazole) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — US product sales ($M) › Seroquel XR / IR (quetiapine) — US YoY (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — US product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Europe product sales ($M) › Seroquel XR / IR (quetiapine) — Europe YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Europe product sales ($M) › Seroquel XR / IR (quetiapine) — Europe YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Europe product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW YoY actual (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW YoY CER (%)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW product sales ($M)
  • Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M)
  • Intangible Assets by Medicine, Inventories, PP&E, Legal Provisions & Tax › Net intangible assets carrying value ($M) › Medicine intangible — MSD / Merck alliance option & co-promotion ($M)
  • U.S. Pharmaceutical Industry & Healthcare Spending Context (FRED / BLS / Census / BEA) › U.S. Retail Sales — Pharmacies and Drug Stores, Seasonally Adjusted ($M) › U.S. Retail Sales — Pharmacies and Drug Stores, Not Seasonally Adjusted ($M)
  • U.S. Pharmaceutical Industry & Healthcare Spending Context (FRED / BLS / Census / BEA) › U.S. Retail Sales — Pharmacies and Drug Stores, Seasonally Adjusted ($M)
  • Epidemiology Data Tables › Patient prevalence & incidence across Oncology / CVRM / R&I / Rare Disease (Missing FY2025 between FY2024 and FY2026, causing a break in the annual series)
  • Form 6-K Block Listing Six-Monthly Interim Reviews (2021–2026) › Unallotted share balances under employee share schemes (Disclosed semi-annually, irregular quarterly/annual periods)

Dữ liệu cập nhật 2026-10-28.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Core — Revenue Structure (Product Sales, Alliance Revenue, Collaboration) & Revenue by Geographic Market

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của AstraZeneca

See a number that looks wrong?